Hilleroed, Denmark

Simon Bjerregaard Jensen

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 27(Granted Patents)


Location History:

  • Frederiksberg, DK (2014)
  • Hillerød, DK (2016)
  • Hilleroed, DK (2018 - 2021)

Company Filing History:


Years Active: 2014-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Simon Bjerregaard Jensen

Introduction

Simon Bjerregaard Jensen is a notable inventor based in Hilleroed, Denmark. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of tablet formulations that incorporate GLP-1 peptides. With a total of four patents to his name, Jensen's work is paving the way for advancements in drug delivery systems.

Latest Patents

Among his latest patents, one includes a "Tablet formulation comprising a GLP-1 peptide and a delivery agent." This invention relates to solid compositions that utilize a GLP-1 peptide along with a delivery agent, such as SNAC, enhancing the efficacy of the peptide. Another significant patent is titled "Tablet formulation comprising semaglutide and a delivery agent," which also focuses on solid compositions that incorporate a GLP-1 peptide and a delivery agent, showcasing his innovative approach to drug formulation.

Career Highlights

Simon Bjerregaard Jensen is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His work at Novo Nordisk has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Jensen has collaborated with esteemed colleagues such as Per Sauerberg and Flemming Seier Nielsen. These collaborations have fostered an environment of innovation and have led to the successful development of new pharmaceutical products.

Conclusion

Simon Bjerregaard Jensen's contributions to the field of pharmaceutical formulations are noteworthy, particularly in the area of GLP-1 peptide delivery systems. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…